Document is current
Any future updates will be listed below
-
Authors
Kalaitzidis, Demetrios
Ghonime, Mohammed
Chain, Robert
Jaishankar, Nivedita
Settipane, Davis
Padalia, Zinkal
Zakas, Lauren
Kuppuraju, Meghna
Tetteh, Paul
Dequeant, Mary-Lee
Karnik, Sushant
Massilamany, Chandirasegaran
McEwan, Brigid
Dar, Henia
Allen, Melanie
Serwer, Laura
Nguyen, Thao
Butler-Gauthier, Melanie
Sripakdeevong, Parin
Nagar, Shashwat
Tang, Yin
Flanagan, Nicole
Huang, Elaine
Phuyal, Shashwant
Dunn, Andrew
Koch, Elizabeth
Sula, Erisa
Waldman, Jacob
Zhang, Maria Lei
Loaiza, Cristian
Thorstensen, Erin
Steiger, Keith
Schum, Katie
Urbaez, Kayla
Ma, Anna
Weaver, Annie Yang
Finch, Christopher
Cohen, Sarah
Morrow, PK
Benton, Mark
Terrett, Jonathan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04035434 at ClinicalTrials.govnct05643742 at ClinicalTrials.govDocuments that mention this clinical trial
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
https://doi.org/10.1136/jitc-2023-sitc2023.0274
Documents that mention this clinical trial
274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency
https://doi.org/10.1136/jitc-2023-sitc2023.0274
- License Information
